For formula-fed infants For healthcare professional use only



Sanulac Nutritionals Research Update

Sn-2 palmitate. More than just softer stools.

IMPORTANT STATEMENT: Breastfeeding is best for babies. It has benefits for the infant, such as reducing infection risk, and for the mother. It is important to have a healthy balanced diet in preparation for, and during breastfeeding. Infant formula is designed to replace breast milk when an infant is not breastfed. Breastfeeding can be negatively affected by introducing partial bottle-feeding, and reversing a decision not to breastfeed is difficult. Infant formula must be prepared and used as directed. Unnecessary or improper use of infant formula, such as not properly boiling water or sterilising feeding equipment, may make your baby ill. Social and financial implications, including preparation time and the cost of formula, should be considered when selecting a method of infant feeding.

Overview

Recent evidence suggests that in addition to softer stools, bone mineral content at 4 months may be increased in infants fed *sn*-2 palmitate enriched formula. Here we take a closer look at one of the largest studies to date investigating the comparative effects of infant formula containing different levels of *sn*-2 palmitate.¹¹

In human milk, one of the main saturated fatty acids (palmitic acid), is found predominantly in the middle (*sn*-2) position of the triglyceride. This structure is known as *sn*-2 palmitate. A greater proportion of *sn*-2 palmitate is associated with softer infant stools and increased absorption of calcium and fatty acids.^{1,2} The recently published Béghin (et al) study helps to improve our understanding on the fate of the previously observed increase in calcium absorption, by measuring the bone mineral content of infants fed infant formula containing increased proportions of *sn*-2 palmitate.¹¹

Study Summary

Study Title: Growth, stool consistency and bone mineral content in healthy term infants fed *sn*-2 palmitate-enriched starter infant formula: A randomised, double-blind, multicentre clinical trial.

Béghin L et al Clinical Nutrition. 2019 June;38(3):1023-1030

Study Population: Healthy term infants (37-42 weeks gestation) aged 1 to 7 days at enrollment.

Number of subjects: n=488

Study Design: Randomised, double-blind, multicentre trial with three parallel groups

Methods: The infants were exclusively formula-fed from 1 week to 4 months with one of three study formula: **1) Control formula**^{*} **(CF)** with 16% of total palmitate in the *sn*-2 position, **2) Experimental formula 1** (EF1) with 43% of total palmitate in the *sn*-2 position, **3) Experimental formula 2** (EF2) with 50.9% of total palmitate in the *sn*-2 position. Weight gain, stool consistency and digestive tolerance were monitored throughout the study period and bone mineral density was measured by dual-energy x-ray absoptiometry at 4 months of age.

Results: Bone mineral content at 4 months was significantly higher in the infants fed the experimental formulae (EF1 p= 0.0012 and EF2 p=0.0002) when compared to the control formula. Intention-to-treat analysis also showed softer stools in the *sn*-2 palmitate enriched formula groups when compared with the control formula (</=0.01) up to 2 months of age.

Conclusion: Formula enriched with *sn*-2 palmitate increases bone mineral content at 4 months of age and is safe and well tolerated.

What this study adds: Previous research has suggested that calcium absorption is improved with infant formula enriched with *sn*-2 palmitate.⁷⁻¹⁰ This large study provides further clarification on the fate of calcium absorbed from *sn*-2 palmitate enriched formula, by showing an increased bone mineral content when compared to standard infant formula.

.....

*Standard infant formula with innate levels of palmitic acid in sn-2 position

"The studies have consistently shown that a higher sn-2 palmitate proportion in formula is associated with improved absorption of calcium and fat..."


- ESPGHAN 2019⁷

Infancy is an important stage for calcium intake as it is deposited into bone at a proportionately higher rate during the first year of life compared to other life stages.⁴ Studies have suggested that the calcium found in human milk is absorbed at a higher rate than from typical cows-milk based formula.4-6

A number of studies have indicated that calcium and fatty acid absorption is improved with infant formula containing increased proportion of *sn*-2 palmitate.⁷⁻¹⁰

It was less clear whether the observed improvement in calcium absorption contributed to an increased bone mineral content. Recent research findings have improved knowledge in this area.¹¹





Adapted from Beghin et al, 2019. Standard CF cows milk formula mean 112g +/- 19g (16% of total palmitate at sn-2 position), EFI (43% of total palmitate at sn-2 position) 110g +/- 20g, EF2 (50.9% of total palmitate at sn-2 position)121+/- 20. EF1 vs CF p= 0.0012, EF2 vs CF p=0.0002

.....

What is *sn*-2 palmitate?

Triglycerides in human milk are unusual as the fatty acids are bonded in a distinctive order. One major fatty acid in human milk, palmitic acid, is mainly (~70%) located at the sn-2 (middle) position on the triglyceride.^{1,2}

This typical structure is referred to as *sn*-2 palmitate and may help explain the improved bioavailability of some nutrients in breast-milk.1,3

Increased sn-2 palmitate in infant formula significantly improves bone mineral count (BMC)¹¹


A recent large (n=488) randomised study investigated the effect of increasing *sn*-2 palmitate content of infant formula on bone mineralisation in healthy term infants 1-7 days old. 11


Bone mineral content at 4 months of age was found to be significantly higher for the sn-2 palmitate enriched formula groups (vs control formula EFI p=0.0012, EF2 p=0.0002) measured by dual-energy x-ray absorptiometry scan (DEXA).¹¹

In addition, the infants fed *sn*-2 palmitate enriched formula experienced softer stools to 2 months of age.11

How does an increase in *sn*-2 palmitate help improve calcium bioavailability?

The increase in *sn*-2 palmitate in infant formula provides a way to decrease the proportion of *sn*-1 and *sn*-3 palmitate content. Palmitic acid bound at the sn-1 and sn-3 position are associated with the formation of insoluble calcium-palmitate soaps which may prevent absorption of calcium, increase calcium losses and contribute to the formation of harder stools.^{1,2,12} In contrast, palmitic acid bound at the *sn*-2 position is better absorbed leading to less calcium palmitate soaps, increased calcium absorption and softer stools,^{1,2,11,12}





stools P=0.026 Formula with sn-2 palmitate Control term formula enriched fat blend

Test: sn-2 palmitate enriched formula

S-26 Alula Gold Newborn

Providing nutritional support for the 4 key pillars of Paediatric development and function



Digestion

- S-26 Alula Gold Newborn is enriched with *sn*-2 palmitate. (0.33g/100mL).
- *Sn*-2 palmitate enriched infant formula may result in softer stools.^{9,11,12}
- *Sn*-2 palmitate enriched infant formula is associated with increased bone mineral content at 4 months of age and increased calcium bioavailability.⁷⁻¹¹
- Easy to digest whey dominant, whole (intact) protein.^{13,14}

• Whey:casein ratio 65:35



References: 1. Innis, S.M., 2011. AdvNutr, 2(3), pp275-283 2. Bar-Yoseph, F., et al. 2013. PLEFA 89(4),PP 139-143. 3. Carnielli, V.P., et al. 1996, JPGN, 23(5), pp 553-560 4. IOM (Institute of Medicine). 2011. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press. 5. NHMRC 2014, Nutrient Reference Values for Australia and New Zealand: Canberra, NHMRC 6. Hicks et al. 2012, BMC Pediatrics, 12:118 7. Bronsky J, et al. J Pediatr Gastroenterol Nutr. 2019 May;68(5):742-760. 8. Nowacki, J et al Nutr J. 2014 Nov 5;13:105 9. Kennedy K et al, Am J Clin Nutr. 1999 Nov; 70(5): 920-7 10. Litmanovitz, I. et al, Calcif Tissue Int. 2013 Jan;92(1):35-41 11. Béghin L, et al. Clin Nutr. 2019 Jun;38(3):1023- 1030 12. Yao, M. et al. JPGN 2014:59: 440-448 13. Lönnerdal, B.,2003. Am J Clin Nutr, 77, pp. 1537S-43S 14. Martin, C., Ling, P. & Blackburn, G., 2016, Nutrients, 8 (279), pp. 1-11

® S-26 is a registered trade marks used under licence. Distributed by Sanulac Nutritionals Australia Pty Ltd. Level 1, 42-44 Chandos St, St Leonards, NSW 2065 Australia. 8/02/2021.